Effect of the Dual 5α-Reductase Inhibitor Dutasteride on Markers of Tumor Regression in Prostate Cancer

The document discussed the effects of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. It highlighted that dutasteride inhibited androgen action and promoted cell death in prostate cancer cell lines, specifically the LNCaP line. The study referenced various research articles that supported the differential expression of 5α-reductase isoenzymes in normal and pathological prostate tissues, and the impact of androgen deprivation on prostatic cancer. The findings suggested that dutasteride could be a potential therapeutic agent in managing prostate cancer by inducing atrophy and apoptosis in cancerous cells.